Clinical Use of CSF Neurotransmitters Lance H. Rodan, MD, K. Michael Gibson, PhD, Phillip L. Pearl, MD Pediatric Neurology Volume 53, Issue 4, Pages 277-286 (October 2015) DOI: 10.1016/j.pediatrneurol.2015.04.016 Copyright © 2015 Elsevier Inc. Terms and Conditions
Figure 1 Monoamine synthesis pathway. Metabolic pathways of biogenic monoamine neurotransmitters. AADC, aromatic-L-amino acid decarboxylase; ALDH, aldehyde dehydrogenase, BH2, quinonoid dihydrobiopterin; BH4, tetrahydrobiopterin; COMT, catechol-O-methyltransferase; DBH, dopamine β-hydroxylase; GTP, guanosine triphosphate; ; GTPCH1, GTP-cyclohydrolase I; 5-HIAA, 5-hydroxyindoleacetic acid; 5-HTP, 5 hydroxytryptophan; HVA, homovanillic acid; MAO, monoamine oxidase; MHPG, 3-methoxy-4-hydroxyphenylglycol; PNMT, phenylethanolamine N-methyltransferase; Trp OHase, tryptophan hydroxylase; Tyr OHase, tyrosine hydroxylase; VMA, vanillylmandelic acid. Pediatric Neurology 2015 53, 277-286DOI: (10.1016/j.pediatrneurol.2015.04.016) Copyright © 2015 Elsevier Inc. Terms and Conditions
Figure 2 Gamma aminobutyric acid (GABA) metabolic pathway. Pediatric Neurology 2015 53, 277-286DOI: (10.1016/j.pediatrneurol.2015.04.016) Copyright © 2015 Elsevier Inc. Terms and Conditions
Figure 3 Serine synthesis pathway. (The color version of this figure is available in the online edition.) Pediatric Neurology 2015 53, 277-286DOI: (10.1016/j.pediatrneurol.2015.04.016) Copyright © 2015 Elsevier Inc. Terms and Conditions